Home›Research›Compare›5-Amino-1MQ vs CJC-1295 (without DAC)
Peptide Comparison5-Amino-1MQ vs CJC-1295 (without DAC)
5-Amino-1MQ
5-Amino-1-methylquinolinium
49 providers listed
CJC-1295 (without DAC)
CJC-1295
Half-life: ~30 minutes
451 providers listed
5-Amino-1MQ and CJC-1295 (without DAC) target different goals — 5-Amino-1MQ for fat cell reduction, CJC-1295 (without DAC) for GH and IGF-1 elevation. They're compared here for reference, not as direct substitutes.
5-Amino-1MQ
Evidence
Half-life
—
CJC-1295 (without DAC)
Evidence
Half-life
~30 minutes
5-Amino-1MQ and CJC-1295 (without DAC) target different goals — 5-Amino-1MQ for Metabolic, CJC-1295 (without DAC) for GH / IGF Axis. They're compared here for reference; there isn't a single “better” choice between them.
5-Amino-1MQ
CJC-1295 (without DAC)
CJC-1295 (without DAC)
Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)…
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Imp…
Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune syst…
About 5-Amino-1MQ
Inhibits NNMT enzyme, increasing SAM (S-adenosylmethionine) availability. Alters adipocyte gene expression to reduce fat cell size and may increase brown adipose tissue activity via epigenetic mechanisms.
About CJC-1295 (without DAC)
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Lacking the Drug Affinity Complex, it is not albumin-bound and clears within roughly half an hour, producing discrete GH pulses rather than the sustained elevation of the DAC form.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
5-Amino-1MQ
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
CJC-1295 (without DAC)
Class-based (investigational)
Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceCJC-1295 (without DAC)
Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.
5-Amino-1MQ
CJC-1295 (without DAC)
Where to source these peptides
5-Amino-1MQ
49 listed
Browse directory →
Providers offeringCJC-1295 (without DAC)
451 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
Related Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 27, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). 5-Amino-1MQ vs CJC-1295 (without DAC) — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/5-amino-1mq/cjc-1295